​​​​​​​EuroBiotech:​​​ ​​​More​​​ ​​​Articles​​​ ​​​of​​​ ​​​Note


> Galapagos unveiled Dr. Walid Abi-Saab as its CMO. Abi-Saab joins Galapagos from Shire, where he rose to the role of therapeutic area head for gastrointestinal, endocrinology and metabolism conditions. Prior to joining Shire, Abi-Saab worked on clinical development at companies including Abbott Laboratories, Novartis and Pfizer. Release

> Shares in NeuroVive Pharmaceutical rose 70% after it posted preclinical data in hepatocellular cancer. The Swedish biotech said some of its sanglifehrin-based compounds “exert unexpectedly potent anticancer effects” in preclinical. With NeuroVive’s share price at a low ebb following failures in the clinic, the early-stage data were enough to spark a surge in its value. Release

> Malin invested in Wren Therapeutics, a spinout of the University of Cambridge, UK, and Lund University, Sweden. Wren is looking at protein misfolding diseases using a platform that emerged from research at the two academic centers. Malin, an investment fund helmed by Kelly Martin, has a 33% stake in Wren, and an option to up its holding to 67%. Release

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

> Zealand Pharma received $10 million (€9 million) from Sanofi after the European Union approved Suliqua. The milestone stems from a deal that gave Sanofi access to Zealand’s GLP-1 analogue lixisenatide. Zealand is eligible to receive up to $100 million more in milestones. Release

> FDA granted rare pediatric disease designation to Lysogene’s LYS-GM101 in the neurodegenerative disease GM1 gangliosidosis. LYS-GM101 is a gene therapy designed to equip people to produce their own lysosomal acid beta-balactosidase enzyme, and, in doing so, stop the neurological damage caused by the condition. Release

> CellProthera raised €8.3 million ($8.9 million) to continue its phase 1/2b trials and prepare for a phase 3 study. The preparations for the phase 3 will entail setting up cell therapy centers in Europe, the U.S. and Canada. CellProthera is focused on using autologous stem cells to regenerate the heart following acute myocardial infarction. Release

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.